Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The recent and pending introduction of new antipsychotic medications carries the hope of a significant advance in the treatment of schizophrenia. Although the propensity of these agents to cause fewer motor side-effects than conventional neuroleptics may lead to improved compliance and clinical effectiveness, the promise of a significant impact upon the lives of patients may primarily reside in the evidence that the atypicals alleviate negative features such as emotional flattening, social withdrawal and impoverished speech. Auditory hallucinations and delusional thinking are the more dramatic expressions of illness, but these negative symptoms, along with neuropsychological deficits, are arguably more responsible for the persisting debilitation exhibited by schizophrenics (McKay, 1980; Pogue-Geile & Harrow, 1985; Breier et al. 1991; Crow, 1991; Mukherjee et al. 1991; Kane & Freeman, 1994; Perlick et al. 1992; Green, 1996; Green et al. 1997). Negative symptoms and neuropsychological deficits are minimally responsive to conventional neuroleptics (Goldberg et al. 1991; Meltzer, 1992; Lee et al. 1994; Meltzer et al. 1994), leaving schizophrenics ill-equipped to deal with the demands of normal living. The claim is often made that clozapine alleviates both negative symptoms and neurocognitive deficits (e.g. Meltzer, 1995a). Although there is hope that the newer antipsychotics will do likewise, the evidence for neurocognitive gains in particular is, so far, limited. Only a few studies of the effects of novel antipsychotics (such as risperidone, olanzapine, sertindole and related in-trial agents) on neuropsychological functioning have been undertaken. When effects have been demonstrated, their significance has remained unclear. This state of affairs is unsatisfactory, as a positive impact upon neuropsychological functioning would be of interest for more than just clinical reasons. An amelioration of cognitive deficiencies would suggest that these features are not inexorably tied to an irreversible pathology, such as gross neurodevelopmental aberrations or loss of neural tissue. Rather, such gains would suggest a treatable underlying pathophysiology, lending hope to other treatments, including cognitive rehabilitation. Since these deficits are increasingly viewed as fundamental to our conceptions of severe psychiatric illness (Goldberg et al. 1991; Green, 1996; Nuechterlein & Subotnik, 1996), neurocognitive changes might reciprocally shed light on these medications and schizophrenia. Finally, differential effects on cognition across medications should be factored into cost–benefit analyses, particularly when these effects are accompanied by broader adaptive functioning gains. Is there any reason to believe that the novel antipsychotics will significantly improve the functional capacities of schizophrenics? Several considerations are relevant, including purported action mechanisms, animal behaviour findings, neurological effects, negative symptoms effects and existing cognitive outcome data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · cited 2×
“The P50 abnormality correlates with impaired performances on measures of sustained attention and word recognition, possibly reflecting failures in neural mechanisms that filter sensory input to higher brain centres (Freedman et al. 1997) ; thus distractibility results.”
BackgroundNeuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
Saykin, A. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020048005 · Cited by 1,086
Cited by
Cannabis, a complex plant: different compounds and different effects on individuals
Atakan, Z. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312457586 · Cited by 544
The Emotional Impact of Bullying and Cyberbullying on Victims: A European Cross‐National Study
Ortega, R., Elipe, P., Mora‐Merchán, J. A., Genta, M. L., Brighi, A., Guarini, A., Smith, P. K., Thompson, F., & Tippett, N. (2012) · Aggressive Behavior · doi:10.1002/ab.21440 · Cited by 359
Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies
Solé, B., Jiménez, E., Torrent, C., Reinares, M., Bonnin, C. D. M., Torres, I., Varo, C., Grande, I., Valls, E., Salagre, E., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx032 · Cited by 299
Dickerson, F. B., Boronow, J. J., Stallings, C., Origoni, A. E., Ruslanova, I., & Yolken, R. H. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.5.466 · Cited by 209
“Cognitive deficits do not remit between illness episodes and are generally not responsive to currently available pharmacological treatments.(15) Herpesviruses are enveloped, doublestranded DNA viruses that are capable of infecting humans and many other animal species.”
Oertel-Knöchel, V., Mehler, P., Thiel, C., Steinbrecher, K., Malchow, B., Tesky, V., Ademmer, K., Prvulovic, D., Banzer, W., Zopf, Y., et al. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0485-9 · Cited by 185
Metadata
- Authors
- HAWKINS, K. A., MOHAMED, S., & WOODS, S. W.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 1999-01
- Volume
- 29
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2090774800
- Cited by
- 120
- References
- 3
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.